The value add isn't in the reproducing the original text but doing the research that provides an application for it. For example, if the book in question were a collection of case law, and you went through 1,000s of pages to find a legal argument that won at trial should you be restricted from being able to claim Intellectual Property rights over the application? In that case, the case law text you "photocopied" is a necessary precursor of the actual IP (using it as a winning legal argument).
Except, it's not even that complicated conceptually. As long as you have the mRNA, you essentially have the cDNA as well. And indeed, the mRNA is naturally occuring too. BTW, in terms of conceptual difficulty, this is high school biology.
What they should be able to patent is the method for a new test technique utilizing that cDNA, but they didn't even do that.
But like I said, these moronic gene patents don't apply to us up here in Canada. And I guess the good news for the US is that Myriad's patents are ending soon anyway.
While I'm neither scientist or lawyer, that sounds like what happened here. The company spent countless hours analyzing genes to identify one which causes cancer (BRCA1) and a test to identify who has it. Now you're saying that because "DNA exists in nature" that the company shouldn't be able to claim IP rights over the identification of the BRCA1 gene?
That's exactly what I'm saying. And that's what the Supreme Court ruled in fact.
Except the test part. They didn't develop the technique for the test, and thus they can't have a patent on the test technique. The test is a standard one that had been used for ages.
How the fvck is that fair? And secondly, who would ever spend any time or effort to analyze genes to find which ones have disease-causing impacts if you can't monetize the findings?
Probably the same people who are analyzing genes now. University researchers, and big pharma looking to find new targeted drugs which they can patent.